clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at Adaptive's CLIA-certified lab in Seattle. clonoSEQ testing in MCL has also ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

as a first-line treatment for adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for stem cell transplantation. According to InvestingPro analysis, AstraZeneca ...

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

In the BRIGHT study, bendamustine plus rituximab was evaluated as a first-line treatment for indolent non-Hodgkin lymphoma or mantle cell lymphoma compared with a standard rituximab-chemotherapy ...

Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.